Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

peIF4E as an independent prognostic factor and a potential therapeutic target in diffuse infiltrating astrocytomas

  • Martínez Sáez, Elena
  • Peg, Vicente|||0000-0002-5203-6166
  • Ortega-Aznar, Arantxa
  • Martínez Ricarte, Francisco
  • Camacho, Jessica|||0000-0001-8018-8274
  • Hernández Losa, Javier
  • Ferreres Piñas, Joan Carles|||0000-0001-7742-0239
  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
Malignant transformation in tumors is a complex process requiring accumulation of numerous oncogenic abnormalities. Brain tumors show considerable phenotypic and genetic heterogeneity. In a series comprising diffuse infiltrating astrocytomas () and reactive gliosis, we investigated the main factors associated with signaling pathways. We assessed expression levels and their association with tumor progression and survival. We studied 19 grade astrocytomas, 25 anaplastic astrocytomas (grade ), 60 glioblastomas (grade ), and 15 cases of reactive gliosis. Epidermal growth factor receptor (), , 4E-1, p4E-1, 6, 4E, and pe4E expression levels were evaluated using immunohistochemistry. Expression levels were semiquantitatively evaluated using a histoscore. Immunohistochemistry and were used for 1 mutations. Statistical analysis was based on the following tests: chi-square, Student's t, Pearson correlation, Spearman's rho, and Mann-Whitney; and Kaplan-Meier curves were constructed. A significant increase was observed between grades for expression of total and phosphorylated 4E-1 and for 4E, Ki67, , and cyclin D1. Although expression of ,4E, and Ki67 correlated with survival, only pe4E was an independent predictor of survival in the multivariate analysis. Combining the evaluation of different proteins enables us to generate helpful diagnostic nomograms. In conclusion, cell signaling pathways are activated in s; pe4E is an independent prognostic factor and a promising therapeutic target. Joint analysis of the expression of 4E-1 and pe4E could be helpful in the diagnosis of glioblastoma multiforme in small biopsy samples.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

  • Hergueta-Redondo, Marta
  • Sarrio, David
  • Molina-Crespo, Ángela
  • Vicario, Rocío
  • Bernadó Morales, Cristina|||0000-0003-1376-0407
  • Martínez, Lidia
  • Rojo-Sebastián, Alejandro
  • Serra-Musach, Jordi
  • Mota, Alba
  • Martínez-Ramírez, Ángel
  • Castilla, Maria Ángeles
  • González-Martin, Antonio
  • Pernas, Sonia|||0000-0002-1485-5080
  • Cano, Amparo
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Peg, Vicente|||0000-0002-5203-6166
  • Palacios, José|||0000-0002-6730-5066
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Moreno-Bueno, Gema
Around, 30-40% of HER2-positive breast cancers do not show substantial clinical benefit from the targeted therapy and, thus, the mechanisms underlying resistance remain partially unknown. Interestingly, ERBB2 is frequently co-amplified and co-expressed with neighbour genes that may play a relevant role in this cancer subtype. Here, using an in silico analysis of data from 2,096 breast tumours, we reveal a significant correlation between Gasdermin B (GSDMB) gene (located 175 kilo bases distal from ERBB2) expression and the pathological and clinical parameters of poor prognosis in HER2-positive breast cancer. Next, the analysis of three independent cohorts (totalizing 286 tumours) showed that approximately 65% of the HER2-positive cases have GSDMB gene amplification and protein over-expression. Moreover, GSDMB expression was also linked to poor therapeutic responses in terms of lower relapse free survival and pathologic complete response as well as positive lymph node status and the development of distant metastasis under neoadjuvant and adjuvant treatment settings, respectively. Importantly, GSDMB expression promotes survival to trastuzumab in different HER2-positive breast carcinoma cells, and is associated with trastuzumab resistance phenotype in vivo in Patient Derived Xenografts. In summary, our data identifies the ERBB2 co-amplified and co-expressed gene GSDMB as a critical determinant of poor prognosis and therapeutic response in HER2-positive breast cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts

  • Morancho, Beatriz|||0000-0003-3369-8647
  • Zacarías-Fluck, Mariano F|||0000-0002-7171-4268
  • Esgueva, Antonio|||0000-0002-8622-064X
  • Bernadó Morales, Cristina|||0000-0003-1376-0407
  • Cosimo, Serena Di
  • Prat, Aleix|||0000-0003-2377-540X
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Arribas, Joaquín V|||0000-0002-0504-0664
  • Rubio, Isabel T.|||0000-0003-0035-0679
The pleiotropic cytokine IL-6 accelerates the progression of breast cancer in a variety of preclinical models through the activation of the STAT3 (signal transducer and activator of transcription 3) signaling pathway. However, the proportion of breast cancers sensitive to anti-IL-6 therapies is not known. This study evaluates the efficacy of anti-IL-6 therapies using breast cancer patient derived xenografts (PDXs). During the generation of our collection of PDXs, we showed that the successful engraftment of tumor tissue in immunodeficient mice correlates with bad prognosis. Four PDXs out of six were resistant to anti-IL-6 therapies and the expression of IL-6, its receptor or the levels of phospho-STAT3 (the active form of the signal transducer) did not correlate with sensitivity. Using cell cultures established from the PDXs as well as samples from in vivo treatments, we showed that only tumors in which the activation of STAT3 depends on IL-6 respond to the blocking antibodies. Our results indicate that only a fraction of breast tumors are responsive to anti-IL-6 therapies. In order to identify responsive tumors, a functional assay to determine the dependence of STAT3 activation on IL-6 should be performed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Clinical implications of intratumor heterogeneity, challenges and opportunities

  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
  • Sesé, Marta|||0000-0003-1473-4833
  • Capdevila, Claudia
  • Aasen, Trond|||0000-0003-0763-2695
  • De Mattos-Arruda, Leticia|||0000-0002-4992-3645
  • Diaz-Cano, Salvador J.
  • Hernandez-Losa, Javier|||0000-0003-1526-3201
  • Castellvi, Josep|||0000-0001-5745-9996
In this review, we highlight the role of intratumoral heterogeneity, focusing on the clinical and biological ramifications this phenomenon poses. Intratumoral heterogeneity arises through complex genetic, epigenetic, and protein modifications that drive phenotypic selection in response to environmental pressures. Functionally, heterogeneity provides tumors with significant adaptability. This ranges from mutual beneficial cooperation between cells, which nurture features such as growth and metastasis, to the narrow escape and survival of clonal cell populations that have adapted to thrive under specific conditions such as hypoxia or chemotherapy. These dynamic intercellular interplays are guided by a Darwinian selection landscape between clonal tumor cell populations and the tumor microenvironment. Understanding the involved drivers and functional consequences of such tumor heterogeneity is challenging but also promises to provide novel insight needed to confront the problem of therapeutic resistance in tumors.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

ITGB3-mediated uptake of small extracellular vesicles facilitates intercellular communication in breast cancer cells

  • Fuentes Varela, Pedro|||0000-0001-8471-0197
  • Sesé, Marta|||0000-0003-1473-4833
  • Guijarro, Pedro J.
  • Emperador, Marta|||0000-0002-8538-4319
  • Sánchez-Redondo, Sara
  • Peinado, Héctor|||0000-0002-4256-3413
  • Hümmer, Stefan|||0000-0002-8184-3872
  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
Metastasis, the spread of malignant cells from a primary tumour to distant sites, causes 90% of cancer-related deaths. The integrin ITGB3 has been previously described to play an essential role in breast cancer metastasis, but the precise mechanisms remain undefined. We have now uncovered essential and thus far unknown roles of ITGB3 in vesicle uptake. The functional requirement for ITGB3 derives from its interactions with heparan sulfate proteoglycans (HSPGs) and the process of integrin endocytosis, allowing the capture of extracellular vesicles and their endocytosis-mediated internalization. Key for the function of ITGB3 is the interaction and activation of focal adhesion kinase (FAK), which is required for endocytosis of these vesicles. Thus, ITGB3 has a central role in intracellular communication via extracellular vesicles, proposed to be critical for cancer metastasis. The integrin ITGB3 has been described to play an essential role in breast cancer metastasis, but the precise mechanisms remain undefined. Here the authors describe thus far unknown roles of ITGB3 in the uptake of extracellular vesicles, required for colony growth of breast cancer cells